A detailed history of Versant Capital Management, Inc transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 24 shares of VNDA stock, worth $122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24
Previous 24 -0.0%
Holding current value
$122
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 03, 2024

SELL
$3.47 - $4.61 $825 - $1,097
-238 Reduced 90.84%
24 $0
Q4 2023

Jan 08, 2024

BUY
$3.38 - $4.58 $74 - $100
22 Added 9.17%
262 $1,000
Q3 2023

Oct 11, 2023

BUY
$4.28 - $6.57 $282 - $433
66 Added 37.93%
240 $1,000
Q1 2023

Apr 10, 2023

SELL
$6.18 - $7.99 $4,084 - $5,281
-661 Reduced 79.16%
174 $1,000
Q4 2022

Jan 25, 2023

SELL
$6.87 - $10.96 $185 - $295
-27 Reduced 3.13%
835 $0
Q3 2022

Dec 30, 2022

BUY
$9.44 - $11.76 $47 - $58
5 Added 0.58%
862 $9,000
Q2 2022

Aug 02, 2022

BUY
$9.31 - $11.84 $1,014 - $1,290
109 Added 14.57%
857 $9,000
Q1 2022

Apr 29, 2022

SELL
$10.84 - $16.55 $401 - $612
-37 Reduced 4.71%
748 $8,000
Q4 2021

Jan 06, 2022

BUY
$15.69 - $21.14 $533 - $718
34 Added 4.53%
785 $12,000
Q3 2021

Oct 29, 2021

SELL
$15.35 - $21.27 $1,396 - $1,935
-91 Reduced 10.81%
751 $13,000
Q2 2021

Jul 22, 2021

SELL
$15.71 - $21.51 $5,749 - $7,872
-366 Reduced 30.3%
842 $18,000
Q1 2021

Apr 27, 2021

BUY
$13.42 - $20.28 $1,972 - $2,981
147 Added 13.85%
1,208 $18,000
Q4 2020

Feb 08, 2021

BUY
$9.77 - $13.81 $68 - $96
7 Added 0.66%
1,061 $13,000
Q3 2020

Nov 02, 2020

BUY
$9.32 - $12.02 $2,516 - $3,245
270 Added 34.44%
1,054 $10,000
Q2 2020

Jul 16, 2020

SELL
$9.66 - $12.02 $1,178 - $1,466
-122 Reduced 13.47%
784 $8,000
Q1 2020

Apr 17, 2020

BUY
$7.5 - $16.8 $6,795 - $15,220
906 New
906 $9,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $288M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.